An analgesia circuit activated by cannabinoids
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Although many anecdotal reports indicate that marijuana and its active constituent, delta-9-tetrahydrocannabinol (delta-9-THC), may reduce pain sensation, studies of humans have produced inconsistent results. In animal studies, the apparent pain-suppressing effects of delta-9-THC and other cannabinoid drugs are confounded by motor deficits. Here we show that a brainstem circuit that contributes to the pain-suppressing effects of morphine is also required for the analgesic effects of cannabinoids. Inactivation of the rostral ventromedial medulla (RVM) prevents the analgesia but not the motor deficits produced by systemically administered cannabinoids. Furthermore, cannabinoids produce analgesia by modulating RVM neuronal activity in a manner similar to, but pharmacologically dissociable from, that of morphine. We also show that endogenous cannabinoids tonically regulate pain thresholds in part through the modulation of RVM neuronal activity. These results show that analgesia produced by cannabinoids and opioids involves similar brainstem circuitry and that cannabinoids are indeed centrally acting analgesics with a new mechanism of action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“cannabinoids produce analgesia either in animal models of pain (both acute pain and tonic pain) or in clinical painful conditions (for reviews see: 161,221), and endogenous cannabinoids are tonically released to participate in the control of basal nociceptive threshold (137).”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [137]
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Endogenous Pain Control Systems: Brainstem Spinal Pathways and Endorphin Circuitry
Basbaum, A. I., & Fields, H. L. (1984) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.07.030184.001521 · Cited by 2,687
Self-citationSR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Cadas, H., di Tomaso, E., & Piomelli, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-04-01226.1997 · Cited by 396
The analgesic properties of delta‐9‐tetrahydrocannabinol and codeine
Noyes, R., Brunk, S. F., Avery, D. H., & Canter, A. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518184 · Cited by 378
Research works printed but not linked: 1
- Buxbaum, D., Sanders-Bush, E. & Efron, D. Analgesic activity of tetrahydrocannabinol (THC) in the rat and mouse. Fed. Proc. 28, 735 (1969).
Cited by
Items 201–300 of 411
A role for the endogenous cannabinoid system in the peripheal control of pain initiation
Calignano, A., Rana, G. L., Loubet‐Lescoulié, P., & Piomelli, D. (2000) · Progress in brain research · doi:10.1016/s0079-6123(00)29034-1 · Cited by 37
Meng, I. D., & Harasawa, I. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.02.022 · Cited by 35
“…activity in inhibiting nociceptive transmission (Bederson et al. 1990; Fields et al. 1983b; Foo and Mason 2003; Heinricher et al. 2004a; Heinricher et al. 1994; Heinricher and Neubert 2004; Kaplan and Fields 1991; Kincaid et al. 2006; Meng et al. 1998; Mitchell et al. 1998; Neubert et al. 2004).”
BackgroundSelf-citationThe role of descending fibers from the rostral ventromedial medulla in opioid analgesia in rats
Gilbert, A.-K., & Franklin, K. B. J. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01974-x · Cited by 34
Cheng, H. M., Laviolette, S. R., van der Kooy, D., & Penninger, J. M. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03435.x · Cited by 35
The ‘in’s and out’s’ of descending pain modulation from the rostral ventromedial medulla
Preter, C. C. D., & Heinricher, M. M. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.04.006 · Cited by 65
Lau, B. K., Drew, G. M., Mitchell, V. A., & Vaughan, C. W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12839 · Cited by 35
“In particular, the brainstem circuit comprising the PAG and rostral ventromedial medulla (RVM) is rich in CB1 receptors (Tsou et al., 1998).”
BackgroundResultInfluentialXie, J., Xiao, D., Zhao, J., Hu, N., Bao, Q., Jiang, L., & Yu, L. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201500996 · Cited by 36
Howard, P. D., Twycross, R., Shuster, J. L., Mihalyo, M., & Wilcock, A. (2013) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2013.05.002 · Cited by 39
“opioids).(14,15,29,30) Further, unlike opioid receptors, CB1 persists in the spinal cord after peripheral nerve injury.”
BackgroundMolecular identification of bulbospinal ON neurons by GPER, which drives pain and morphine tolerance
Jiao, Y., Gao, P., Li, D., Ding, X., Meng, Y., Qian, J., Gao, T., Wang, R., Jiang, T., Zhang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154588 · Cited by 39
“The RVM is also an important site for the analgesic effects of endogenous or exogenous opioids, since opioid analgesia is impaired following ablation of the RVM (7, 12).”
Suplita, R. L., Eisenstein, S. A., Neely, M. H., Moise, A. M., & Hohmann, A. G. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.006 · Cited by 33
“Importantly, synthetic cannabinoids directly modulate nociceptive neuronal activity within pain modulatory circuits in the rostral ventromedial medulla to induce analgesia independently of the motor effects of these compounds (Meng et al. 1998).”
BackgroundPreparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors
Dvorácskó, S., Keresztes, A. I., Mollica, A., Stefanucci, A., Macedonio, G., Pieretti, S., Zádor, F., Walter, F. R., Deli, M. A., Kékesi, G., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.037 · Cited by 34
Dvořáková, M., Kubik‐Zahorodna, A., Straiker, A. J., Sedláček, R., Hájková, A., Mackie, K., & Blahoš, J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15383 · Cited by 31
“The inverse agonist rimonabant has been shown to elicit hyperalgesia in TIT in several previous reports (Costa & Colleoni, 1999; Meng et al., 1998; Richardson et al., 1998), while in”
ResultHenderson, A. N., Nealon, C. M., Davis, B. J., Yuill, M. B., Sepúlveda, D. E., Blanton, H. L., Piscura, M. K., Zee, M. L., Haskins, C. P., Marcus, D. J., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107847 · Cited by 34
“, 2002) and rostroventral medulla (Martin et al., 1998; Meng et al., 1998).”
BackgroundEffects of neuropeptide FF system on CB1 and CB2 receptors mediated antinociception in mice
Fang, Q., Han, Z., Li, N., Wang, Z., He, N., & Wang, R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.09.013 · Cited by 33
Benamar, K., Geller, E. B., & Adler, M. W. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.135053 · Cited by 30
“With respect to antinociception, WIN 55,212-2 has been demonstrated to produce it in the paw withdrawal, radiant heat tail-flick, and formalin tests (Martin et al., 1996; Tsou et al., 1996; Meng et al., 1998).”
Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain
Sagar, D. R., Jhaveri, M. D., Richardson, D. S., Gray, R., de Lago, E., Fernández‐Ruíz, J., Barrett, D. A., Kendall, D. A., & Chapman, V. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07162.x · Cited by 33
“Local ECs are known to modulate the spinal processing of acute and inflammatory noxious inputs (Richardson et al., 1997; Meng et al., 1998; Chapman, 1999).”
BackgroundJennings, E. M., Okine, B. N., Olango, W. M., Roche, M., & Finn, D. P. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.05.008 · Cited by 33
“…system in the amygdala plays a key role in the regulation of fear- and pain-related behaviour, and their interactions, in rodents (Finn et al., 2003; Martin et al., 1999; Meng et al., 1998; Roche et al., 2007; Olango et al., 2011; Hohmann et al., 2005; Rea et al., 2013; Marsicano et al., 2002).”
BackgroundMedical Palliation of the Jaundiced Patient with Pruritus
Bergasa, N. V. (2006) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2005.12.008 · Cited by 30
Hass‐Cohen, N., & Findlay, J. C. (2009) · The Arts in Psychotherapy · doi:10.1016/j.aip.2009.02.003 · Cited by 38
Russell, A. L., & McCarty, M. F. (2000) · Medical Hypotheses · doi:10.1054/mehy.1999.1031 · Cited by 29
Samineni, V. K., Premkumar, L. S., & Faingold, C. L. (2011) · Brain Research · doi:10.1016/j.brainres.2011.03.041 · Cited by 28
“Several studies suggest that CB1 receptormediated analgesia may involve disinhibition of PAG antinociceptive output neurons by inhibition of inhibitory interneurons in PAG (Meng et al., 1998; Pan et al., 1990; Vaughan et al., 1999).”
BackgroundCorchero, J., Oliva, J. M., Garcı́a-Lecumberri, C., Martı́n, S., Ambrosio, E., & Manzanares, J. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104040237 · Cited by 28
Li, A. H.-L., Yeh, T., Tan, P. P. C., Hwang, H.-M., & Wang, H. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00030-2 · Cited by 28
The Role of The Rostral Ventromedial Medulla in Stress Responses
Pagliusi, M., & Gomes, F. V. (2023) · Brain Sciences · doi:10.3390/brainsci13050776 · Cited by 34
“Together, these results highlight a possible mechanism for stress-induced nociceptive alterations and cannabinoid-based chronic pain treatments, which may involve the RVM [35,41,43,46,47].”
BackgroundOpioids Disrupt Pro-Nociceptive Modulation Mediated by Raphe Magnus
Hellman, K. M., & Mason, P. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1551-12.2012 · Cited by 31
“Yet, systemic administration of a cannabinoid receptor agonist suppresses ON and OFF cell responses to noxious stimulation and causes antinociception without affecting tonic ON or OFF cell discharge (Meng et al., 1998).”
BackgroundAshton, H. (2002) · Current Opinion in Psychiatry · doi:10.1097/00001504-200205000-00004 · Cited by 37
Zeng, X., Mai, J., Xie, H., Yang, L., & Liu, X. (2023) · The Journal of Headache and Pain · doi:10.1186/s10194-023-01580-7 · Cited by 30
“Furthermore, functional studies have shown that microinjection of cannabinoids into the PAG produces antinociceptive nociception [30, 31].”
BackgroundEsmaeili, M. H., Reisi, Z., Ezzatpanah, S., & Haghparast, A. (2016) · European Journal of Pain · doi:10.1002/ejp.899 · Cited by 28
“It seems that CB1 receptorinduced analgesia is probably mediated through the disinhibition of PAG GABAergic interneurons which exert an intrinsic inhibitory tone on PAG neurons (Pan et al., 1990; Meng et al., 1998; Vaughan et al., 1999; Samineni et al., 2011).”
BackgroundOultram, J. M. J., Pegler, J. L., Bowser, T. A., Ney, L. J., Eamens, A. L., & Grof, C. P. L. (2021) · Biomedicines · doi:10.3390/biomedicines9030234 · Cited by 32
Ultra-low dose naltrexone enhances cannabinoid-induced antinociception
Paquette, J. J., & Olmstead, M. C. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200512000-00001 · Cited by 26
“, 1996) and to increase tailflick latencies (Meng et al., 1998).”
BackgroundInfluentialEndocannabinoid and Muscarinic Signaling Crosstalk in the 3xTg-AD Mouse Model of Alzheimer’s Disease
Llorente‐Ovejero, A., Manuel, I., Lombardero, L., Giralt, M. T., Ledent, C. A., Giménez‐Llort, L., & Rodríguez‐Puertas, R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180137 · Cited by 24
“Ontheotherhand,theanalgesiceffectsofacute CB 1 receptor activation are well known [58], and one mayspeculatethattheadministrationofcannabinoidsmaycontributetoalterthepainperceptionleadingtoincreasethepainthresholdofthefoot -shock[59].”
Posa, L., López-Canul, M., Rullo, L., Gregorio, D. D., Domínguez-López, S., Aboud, M. K., Caputi, F. F., Candeletti, S., Romualdi, P., & Gobbi, G. (2020) · Journal of Pineal Research · doi:10.1111/jpi.12671 · Cited by 31
Deusch, E., Kraft, B., Nahlik, G., Weigl, L. G., HOHENEGGER, M., & Kress, H. G. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00259-5 · Cited by 25
“Other potential indications are pain relief (Noyes et al., 1975; Meng et al., 1998) in certain conditions like multiple sclerosis (Martyn et al., 1995) and spasticity (Petro and Ellenberger, 1981).”
BackgroundOleoylethanolamide affects food intake and sleep–waking cycle through a hypothalamic modulation
Gómez, E. S., Guzmán, K., Pech-Rueda, O., Montes-Rodríguez, C. J., Cisneros, M., & Prospero-Garcia, O. E. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.010 · Cited by 26
Analgesic, anti-inflammatory, and anti-pyretic activity1
Vogel, H. G., Vogel, W. H., Schölkens, B. A., Sandow, J., Müller, G. A., & Vogel, W. F. (2002) · Springer eBooks · doi:10.1007/3-540-29837-1_9 · Cited by 29
Using Cannabis to Treat Cancer-Related Pain
Byars, T., Theisen, E., & Bolton, D. L. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.04.012 · Cited by 31
A nonopioid analgesic acts upon the PAG‐RVM axis to reverse inflammatory hyperalgesia
Vázquez, E., Escobar, W., Ramirez, K., & Vanegas, H. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05280.x · Cited by 25
“inhibit neuronal activity in RVM and thus test its participation in the PAG-induced antinociception (Meng et al., 1998; Lane et al., 2005).”
BackgroundAlkislar, I., Miller, A. R., Hohmann, A. G., Sadaka, A. H., Cai, X., Kulkarni, P., & Ferris, C. F. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.11.015 · Cited by 30
“CB1 receptors, the endogenous cannabinoid receptors and targets of THC, are localized to these nuclei (69,70), and analgesic effects of cannabinoids are dependent on the rostral ventromedial medulla (24).”
BackgroundA Dramatic Response to Inhaled Cannabis in a Woman with Central Thalamic Pain and Dystonia
Chatterjee, A., Almahrezi, Ware, & Fitzcharles (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00426-8 · Cited by 24
Age-related differences in Δ⁹-tetrahydrocannabinol-induced antinociception in female and male rats.
Craft, R., Britch, S. C., Buzitis, N. W., & Clowers, B. (2019) · Experimental and clinical psychopharmacology · doi:10.1037/pha0000257 · Cited by 23
Li, M., Suchland, K. L., & Ingram, S. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.275701 · Cited by 24
“In addition, the RVM is also a necessary site for the anti-nociceptive actions of cannabinoids and several studies have observed synergistic analgesic interactions between cannabinoids and opioids (Meng et al. 1998; Vaughan et al. 1999; Cichewicz, 2004; Vaughan, 2014).”
BackgroundHough, L. B., Nalwalk, J. W., Stadel, R., Timmerman, H., Leurs, R., Paria, B. C., Wang, X., & Dey, S. K. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.036251 · Cited by 27
“…is mostly likely to be the result of modulation of descending analgesic systems projecting to the spinal cord (e.g., in the rostral ventral medulla; Meng et al., 1998), whereas hot-plate analgesia can result from supraspinal (e.g., periaqueductal gray and thalamus) attenuation of ascending…”
BackgroundInfluentialRuginsk, S. G., Uchôa, E. T., Elias, L. L. K., & Antunes‐Rodrigues, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.001 · Cited by 23
Deng, L., Lee, W.-H., Xu, Z., Makriyannis, A., & Hohmann, A. G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.007 · Cited by 24
Chronic Pain: Physiological, Diagnostic, and Management Considerations
Hainline, B. W. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2005.05.010 · Cited by 26
“Additional brain regions are intimately involved in pain modulation through the activation of endogenous neurotransmitters, including acetylcholine, g-aminobutyric acid (GABA), vasoactive intestinal peptide, oxytocin, somatostatin, cholecystokinin, vasopressin, histamine, prolactin, and cannabinoids [9–11].”
BackgroundActivation of brain stem nuclei by improgan, a non-opioid analgesic
Nalwalk, J. W., Svokos, K. A., Taraschenko, O. D., Leurs, R., Timmerman, H., & Hough, L. B. (2004) · Brain Research · doi:10.1016/j.brainres.2004.06.066 · Cited by 22
Paquette, J. J., Wang, H.-Y., Bakshi, K. P., & Olmstead, M. C. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282f15890 · Cited by 27
“…because preliminary data demonstrated that this dose produces maximal antinociception after intravenous administration in the tail-flick test (Meng et al., 1998; Paquette and Olmstead, 2005). ultra-low doses of rimonabant (1.1 or 110 pg/kg) were combined with WIN (125 mg/kg) and administered…”
BackgroundMethodInfluentialPreclinical science regarding cannabinoids as analgesics: An overview
Lynch, M. (2005) · Pain Research and Management · doi:10.1155/2005/169093 · Cited by 20
“Furthermore, microinfusion with the cannabinoid agonist WIN55,212-2 directly into the RVM in rats leads to increased ‘off-cell’ activity with increased tail-flick latencies, indicating that cannabinoids act directly within the RVM to affect off-cell activity (41).”
BackgroundIrving, A. J., Rae, M. G., & Coutts, A. A. (2002) · The Scientific World JOURNAL · doi:10.1100/tsw.2002.139 · Cited by 30
Salas, R., Ramirez, K., Vanegas, H., & Vázquez, E. (2016) · Brain Research · doi:10.1016/j.brainres.2016.10.001 · Cited by 21
The endocannabinoid system, a novel and key participant in acupuncture’s multiple beneficial effects
Hu, B., Bai, F., Xiong, L., & Wang, Q. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.006 · Cited by 23
“Furthermore, microinjection of the GABAa receptor agonist muscimol into the RVM reportedly blocked the antinociceptive effect of systemic WIN55,212-2 administration, as measured using the tail-flick test in rats (Meng et al., 1998).”
Cannabis: Time for Scientific Evaluation of This Ancient Remedy?
Sharpe, P., & Smith, G. (2000) · Anesthesia & Analgesia · doi:10.1097/00000539-200002000-00001 · Cited by 21
Ebrahimzadeh, M. A., & Haghparast, A. (2011) · Brain Research · doi:10.1016/j.brainres.2011.08.028 · Cited by 22
Xiao, A., Zhao, Y. G., & Duan, E. K. (2002) · Molecular Human Reproduction · doi:10.1093/molehr/8.7.651 · Cited by 26
“, 1998), and exerts a wide spectrum of central and peripheral effects (Calignano et al., 1998; Meng et al., 1998; Murillo-Rodriguez et al., 1998).”
BackgroundGao, T., Li, D., Qian, J., Ding, X., Zheng, Y., Wu, M., Meng, L., Jiao, Y., Gao, P., Luo, P., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.2592-20.2021 · Cited by 24
“Indeed, the PAG-RVM is enriched with the m type opioid receptor (MOR), the activation of which results in powerful analgesia (Meng et al., 1998; Eippert et al., 2009; Harasawa et al., 2016).”
BackgroundEffect of styrene maleic acid WIN55,212-2 micelles on neuropathic pain in a rat model
Linsell, O., Brownjohn, P. W., Nehoff, H. L., Greish, K. F., & Ashton, J. C. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2014.997737 · Cited by 19
Smoked Marijuana as Medicine: Not Much Future
Kalant, H. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100497 · Cited by 17
New tricks for an old slug: descending serotonergic system in pain.
Wei, F., Gu, M., & Chu, Y. (2012) · PubMed · Cited by 26
Amyotrophic Lateral Sclerosis and Pain: A Narrative Review from Pain Assessment to Therapy
Pota, V., Sansone, P., Sarno, S. D., Aurilio, C., Coppolino, F., Barbarisi, M., Barbato, F., Fiore, M., Cosenza, G., Passavanti, M. B., et al. (2024) · Behavioural Neurology · doi:10.1155/2024/1228194 · Cited by 23
“Cannabinoid receptor agonists cause analgesic e ff ects in acute and chronic pain states via spinal and supraspinal pathways, similarly to opioids [200, 201].”
Activity of Murine Raphe Magnus Cells Predicts Tachypnea and On-Going Nociceptive Responsiveness
Hellman, K. M., Brink, T. S., & Mason, P. (2007) · Journal of Neurophysiology · doi:10.1152/jn.00904.2007 · Cited by 20
Analgesic, Anti-inflammatory, and Anti-pyretic Activity
Vogel, H. G. (2007) · Springer eBooks · doi:10.1007/978-3-540-70995-4_9 · Cited by 20
Hernández, N., & Vanegas, H. (2001) · Pain · doi:10.1016/s0304-3959(00)00452-8 · Cited by 17
“, 1991; Heinricher and Kaplan, 1991); and (c) the antinociception produced by systemic administration of cannabinoid agonists (Meng et al., 1998).”
Cannabinoids for the Treatment of Pain: An Update on Recent Clinical Trials
Ware, M., & Beaulieu, P. (2005) · Pain Research and Management · doi:10.1155/2005/847562 · Cited by 17
“As reviewed elsewhere in this supplement, the mechanisms of cannabinoid action, which have recently been identified, provide evidence for a pain pathway mediated by cannabinoids (1).”
BackgroundPalliative Schmerztherapie, Cannabinoide
Radbruch, L., & Elsner, F. (2005) · Der Internist · doi:10.1007/s00108-005-1442-5 · Cited by 21
Llorente‐Berzal, A., McGowan, F., Gaspar, J. C., Rea, K., Roche, M., & Finn, D. P. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.11.005 · Cited by 18
Doğrul, B. N., Kopruszinski, C. M., Dolatyarieslami, M., Watanabe, M., Luo, S., de Souza, L. H. M., Vizin, R. C. L., Yue, X., Palmiter, R. D., Navratilova, E., et al. (2024) · Pain · doi:10.1097/j.pain.0000000000003360 · Cited by 18
Borges, R. S., & da Silva, A. B. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00093-4 · Cited by 21
Pharmacologie des dérivés cannabinoïdes : applications au traitement de la douleur ?
Beaulieu, P., & Rice, A. S. C. (2002) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/s0750-7658(02)00663-9 · Cited by 19
Virtual library docking for cannabinoid-1 receptor agonists with reduced side effects
Tummino, T. A., Iliopoulos‐Tsoutsouvas, C., Braz, J. M., O’Brien, E. S., Stein, R. M., Craik, V., Tran, N. K., Ganapathy, S., Liu, F., Shiimura, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57136-7 · Cited by 25
“We have updated the Supplemental information file with more detail on the synthetic schemes, including specific starting materials and their catalog numbers for each compound.”
Bragança, V. A. N., de França, T. G., de Jesus, A. C. S. P. S., Palheta, I. C., Melo, F. P. A., das Neves, P. A. P. F. G., Lima, A. H., & Borges, R. S. (2020) · Chemical Data Collections · doi:10.1016/j.cdc.2020.100345 · Cited by 17
Preclinical Studies of Posttraumatic Headache and the Potential Therapeutics
Tanaka, M., & Zhang, Y. (2022) · Cells · doi:10.3390/cells12010155 · Cited by 16
Esmaeili, M. H., Reisi, Z., Ezzatpanah, S., & Haghparast, A. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000277 · Cited by 17
Mal, J., Xiaol, T., Changl, C., Gaol, L., Wangl, X., Gaol, G., & Yu, Y. (2011) · European Journal of Pain · doi:10.1016/j.ejpain.2011.04.003 · Cited by 16
“, 2001), cannabinoids (Meng et al., 1998) and glutamate receptors (Johansen and Fields, 2004) might be involved in descending inhibitory influences on pain, the detailed molecular and synaptic mechanisms in ACC-mediated analgesic effects needed further investigations.”
BackgroundDifferential modulation of withdrawal reflexes by a cannabinoid in the rabbit
Jenkins, S., Worthington, M., Harris, J. E., & Clarke, R. W. (2004) · Brain Research · doi:10.1016/j.brainres.2004.03.045 · Cited by 16
Auh, Q.-S., Chun, Y. H., Melemedjian, O. K., Zhang, Y., & Ro, J. Y. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.07.009 · Cited by 14
“The synergistic and additive drug effects can also be explained by simultaneous activation of opioid and cannabinoid receptors at multiple levels of brain circuitry involving brain areas such as PAG, RVM and the spinal cord, where these receptors are co-expressed [14, 15, 25, 29].”
BackgroundTian, L., Qiang, T., Liu, S., Zhang, B., Zhang, Y., Zhang, B., Hu, J., Zhang, J., Qi, L., Ke, C., et al. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108795 · Cited by 15
No more pain upon G q‐protein‐coupled receptor activation: role of endocannabinoids
Hu, S. S., Ho, Y., & Chiou, L. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12475 · Cited by 21
“Meng et al. (1998) showed that systemic administration of cannabinoids can modulate the ON and OFF cell activity in the RVM as do opioids, suggesting systemic cannabinoid-induced antinociception through a similar mechanism to that of opioids, by activating the descending pain inhibitory pathway.”
BackgroundRetractedHow do we manage chronic pain?
Schaible, H., & Vanegas, H. (2000) · Best Practice & Research Clinical Rheumatology · doi:10.1053/berh.2000.0114 · Cited by 20
The Brainstem and Nociceptive Modulation
Heinricher, M. M., & Ingram, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.24236-3 · Cited by 14
Brooks, J. W. (2002) · Current Anaesthesia and Critical Care · doi:10.1054/cacc.2002.0406 · Cited by 17
Hitomi, S., Kross, K., Kurose, M., Porreca, F., & Meng, I. D. (2016) · Cephalalgia · doi:10.1177/0333102416648655 · Cited by 17
Self-citationPros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies
Irrera, N., Bitto, A., Sant’Antonio, E., Lauro, R., Musolino, C., & Allegra, A. (2021) · Molecules · doi:10.3390/molecules26133866 · Cited by 13
Identification of the role of endogenous cannabinoids in pain modulation: strategies and pitfalls
Walker, J. M., Huang, S. M., Strangman, N. M., & Sañudo-Peña, M. C. (2000) · Journal of Pain · doi:10.1016/s1526-5900(00)90085-3 · Cited by 12
Significance of Cannabinoid CB1 Receptors in Improgan Antinociception
Gehani, N. C., Nalwalk, J. W., Razdan, R. K., Martin, B. R., Sun, X., Wentland, M. P., Abood, M. E., & Hough, L. B. (2007) · Journal of Pain · doi:10.1016/j.jpain.2007.05.015 · Cited by 13
History of Neurological Disorders in Persian Medicine
Bayan, L., Mousavi, S. M. M., & Gorji, A. (2013) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 11
Agmatine enhances cannabinoid action in the hot-plate assay of thermal nociception
Aggarwal, S., Shavalian, B., Kim, E., & Rawls, S. M. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.06.004 · Cited by 12
No Evidence of Altered Reactivity to Experimentally Induced Pain Among Regular Cannabis Users
Pierre, M. S., Russo, E. B., & Walsh, Z. (2020) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000844 · Cited by 11
Bogdan, R., Carré, J. M., & Hariri, A. R. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_182 · Cited by 10
“physiological (Calignano et al. 1998; Meng et al. 1998) and advanced behavioral”
How cannabis works in the brain
Iversen, L. L. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511543630.004 · Cited by 10
Targeting the Cannabinoid System to Produce Analgesia
Sagar, D. R., Jhaveri, M. D., & Chapman, V. (2009) · Current topics in behavioral neurosciences · doi:10.1007/978-3-540-88955-7_11 · Cited by 13
Johnson, S. H. (2003) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2003.tb00056.x · Cited by 10
Prescribing Cannabinoids for Multiple Sclerosis: Current Issues
Pertwee, R. G. (1999) · CNS Drugs · doi:10.2165/00023210-199911050-00001 · Cited by 10
The Development of Cannabinoids as Therapeutic Agents in the United States
Murray, C. H., Gannon, B. M., Winsauer, P. J., Cooper, Z. D., & Delatte, M. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001121 · Cited by 11
Gilron, I., Blyth, F., Degenhardt, L. J., Forti, M. D., Eccleston, C., Haroutounian, S., Moore, A., Rice, A. S. C., & Wallace, M. S. (2019) · PAIN Reports · doi:10.1097/pr9.0000000000000742 · Cited by 9
Dean, C., Hillard, C. J., Seagard, J. L., Hopp, F. A., & Hogan, Q. H. (2017) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00481.2016 · Cited by 10
Perspectives on biochemical and neurosensory mechanisms for exercise-induced pain inhibition
Micalos, P. S. (2014) · Fatigue Biomedicine Health & Behavior · doi:10.1080/21641846.2014.957484 · Cited by 12
“[37] Central anti-nociceptive brain circuits activated by endocannabinoids have been demonstrated in the rostral ventromedial medulla (RVM),[38] and in the periaqueductal gray (PAG).”
BackgroundOgawa, A., & Meng, I. D. (2008) · Pain · doi:10.1016/j.pain.2008.11.015 · Cited by 9
“Cannabinoid receptor agonists inhibit nociceptive reflexes such as the tail flick through actions at the CB1 receptor [20,45].”
BackgroundSelf-citationLarge library docking for cannabinoid-1 receptor agonists with reduced side effectsPreprint
Tummino, T. A., Iliopoulos‐Tsoutsouvas, C., Bráz, J. M., O’Brien, E. S., Stein, R. M., Craik, V., Tran, N. K., Ganapathy, S., Liu, F., Shiimura, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.27.530254 · Cited by 9
Bitar, N. E., Pollin, B., Huang, G., Mouraux, A., & Bars, D. L. (2015) · Journal of Neurophysiology · doi:10.1152/jn.00695.2015 · Cited by 8
“:3) l), maintained throughout the half an hour observation period, a finding reproduced by Meng et al. (1998).”
Hungry for relief: Potential for neurotensin to address comorbid obesity and pain
Khan, R., Laumet, G. O., & Leinninger, G. M. (2024) · Appetite · doi:10.1016/j.appet.2024.107540 · Cited by 8
“Additionally, a subset of DRG neurons also expresses NtsR1, which is also implicated in pain regulation at the SDH level, although the precise underlying mechanism remains unclear (Zhang et al., 1995).”
Influential
Metadata
- Authors
- Meng, I. D., Manning, B. H., Martin, W. J., & Fields, H. L.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Meng, Ian D.
- Venue
- Nature
- Published
- 1998-09
- Volume
- 395
- Issue
- 6700
- Pages
- 381-383
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1645449597
- Cited by
- 411
- References
- 30
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 8 · 2022: 8 · 2021: 18 · 2020: 13 · 2019: 11 · 2018: 5 · 2017: 11 · 2016: 12 · 2015: 10 · 2014: 13 · 2013: 12 · 2012: 15
- FWCI
- 17.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- cannabinoid analgesia, delta-9-tetrahydrocannabinol, rostral ventromedial medulla, morphine analgesia, endocannabinoids, motor impairment, opioid analgesia
- MeSH terms
- Rimonabant, Analgesia, Animals, Cannabinoids, Male, Medulla Oblongata, Morphine, Morpholines, Motor Activity, Muscimol, Naphthalenes, Neural Pathways, Neurons, Piperidines, Pyrazoles, Receptors, Drug, Rats, Sprague-Dawley, Analgesics, Non-Narcotic, GABA Agonists, Receptors, Cannabinoid, Benzoxazines, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.